These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 2695834)
1. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis. Ahmad I; Sarkar AK; Bachhawat BK Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):85-90. PubMed ID: 2695834 [TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855 [TBL] [Abstract][Full Text] [Related]
3. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B. Ahmad I; Sarkar AK; Bachhawat BK Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711 [TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin-B as a therapeutic measure to control experimental aspergillosis in BALB/c mice. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1990 Dec; 27(6):370-4. PubMed ID: 2102483 [No Abstract] [Full Text] [Related]
5. Preclinical & pharmaceutical testing of liposomal amphotericin B. Gokhale PC; Kotwani RN; Dange SY; Kshirsagar NA; Pandya SK Indian J Med Res; 1993 Apr; 98():75-8. PubMed ID: 8344735 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of experimental invasive pulmonary aspergillosis in rats with liposomal amphotericin B]. Matsuda H; Kohno S; Miyazaki Y; Mitsutake K; Tanaka K; Maesaki S; Iwamoto M; Hashimoto A; Kaku M; Koga H Kansenshogaku Zasshi; 1993 Feb; 67(2):102-9. PubMed ID: 8468494 [TBL] [Abstract][Full Text] [Related]
7. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on aspergillosis virulence and toxicity of liposomal amphotericin B in mice. Moonis M; Ahmad I; Bachhawat BK J Antimicrob Chemother; 1994 Mar; 33(3):571-83. PubMed ID: 8040121 [TBL] [Abstract][Full Text] [Related]
8. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. Owais M; Ahmed I; Krishnakumar B; Jain RK; Bachhawat BK; Gupta CM FEBS Lett; 1993 Jul; 326(1-3):56-8. PubMed ID: 8325389 [TBL] [Abstract][Full Text] [Related]
9. Liposomal hamycin in the control of experimental aspergillosis in mice: effect of phosphatidic acid with and without cholesterol. Moonis M; Ahmad I; Bachhawat BK J Antimicrob Chemother; 1993 Apr; 31(4):569-79. PubMed ID: 8514651 [TBL] [Abstract][Full Text] [Related]
10. Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/C mice. Moonis M; Ahmad I; Bachhawat BK J Drug Target; 1993; 1(2):147-55. PubMed ID: 8069553 [TBL] [Abstract][Full Text] [Related]
11. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin. Moonis M; Ahmad I; Bachhawat BK Indian J Biochem Biophys; 1992 Aug; 29(4):339-45. PubMed ID: 1427960 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins. Chakraborty KK; Naik SR J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435 [TBL] [Abstract][Full Text] [Related]
14. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies. Chakraborty KK; Naik SR Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Olson JA; Adler-Moore JP; Jensen GM; Schwartz J; Dignani MC; Proffitt RT Antimicrob Agents Chemother; 2008 Jan; 52(1):259-68. PubMed ID: 17967910 [TBL] [Abstract][Full Text] [Related]
16. Successful use of liposome encapsulated amphotericin to treat invasive aspergillosis following failure of conventional amphotericin. Richards EM; Apperley JF; Marcus RE Clin Lab Haematol; 1992; 14(2):127-30. PubMed ID: 1633682 [TBL] [Abstract][Full Text] [Related]
17. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery--case report and review of the literature. Coleman JM; Hogg GG; Rosenfeld JV; Waters KD Neurosurgery; 1995 Apr; 36(4):858-63. PubMed ID: 7596522 [TBL] [Abstract][Full Text] [Related]
18. Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Purcell IF; Corris PA Thorax; 1995 Dec; 50(12):1321-3. PubMed ID: 8553311 [TBL] [Abstract][Full Text] [Related]
19. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis. Saxena S; Khan JA; Ghosh PC J Antimicrob Chemother; 1998 Nov; 42(5):635-42. PubMed ID: 9848448 [TBL] [Abstract][Full Text] [Related]
20. Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice. Olson JA; Schwartz JA; Hahka D; Nguyen N; Bunch T; Jensen GM; Adler-Moore JP Med Mycol; 2015 Feb; 53(2):107-18. PubMed ID: 25550388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]